These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 12431965)

  • 1. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer.
    Shepherd FA; Giaccone G; Seymour L; Debruyne C; Bezjak A; Hirsh V; Smylie M; Rubin S; Martins H; Lamont A; Krzakowski M; Sadura A; Zee B
    J Clin Oncol; 2002 Nov; 20(22):4434-9. PubMed ID: 12431965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196.
    Sparano JA; Bernardo P; Stephenson P; Gradishar WJ; Ingle JN; Zucker S; Davidson NE
    J Clin Oncol; 2004 Dec; 22(23):4683-90. PubMed ID: 15570070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
    Goffin JR; Anderson IC; Supko JG; Eder JP; Shapiro GI; Lynch TJ; Shipp M; Johnson BE; Skarin AT
    Clin Cancer Res; 2005 May; 11(9):3417-24. PubMed ID: 15867243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trial.
    Rosenbaum E; Zahurak M; Sinibaldi V; Carducci MA; Pili R; Laufer M; DeWeese TL; Eisenberger MA
    Clin Cancer Res; 2005 Jun; 11(12):4437-43. PubMed ID: 15958628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomised double blind placebo control study of adjuvant treatment with the metalloproteinase inhibitor, Marimastat in patients with inoperable colorectal hepatic metastases: significant survival advantage in patients with musculoskeletal side-effects.
    King J; Zhao J; Clingan P; Morris D
    Anticancer Res; 2003; 23(1B):639-45. PubMed ID: 12680160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial.
    Bramhall SR; Hallissey MT; Whiting J; Scholefield J; Tierney G; Stuart RC; Hawkins RE; McCulloch P; Maughan T; Brown PD; Baillet M; Fielding JW
    Br J Cancer; 2002 Jun; 86(12):1864-70. PubMed ID: 12085177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer.
    Wojtowicz-Praga S; Torri J; Johnson M; Steen V; Marshall J; Ness E; Dickson R; Sale M; Rasmussen HS; Chiodo TA; Hawkins MJ
    J Clin Oncol; 1998 Jun; 16(6):2150-6. PubMed ID: 9626215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Marimastat in patients with advanced pancreatic cancer: a dose-finding study.
    Rosemurgy A; Harris J; Langleben A; Casper E; Goode S; Rasmussen H
    Am J Clin Oncol; 1999 Jun; 22(3):247-52. PubMed ID: 10362330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Marimastat: BB 2516, TA 2516.
    Drugs R D; 2003; 4(3):198-203. PubMed ID: 12757409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II trial of marimastat in advanced pancreatic cancer.
    Evans JD; Stark A; Johnson CD; Daniel F; Carmichael J; Buckels J; Imrie CW; Brown P; Neoptolemos JP
    Br J Cancer; 2001 Dec; 85(12):1865-70. PubMed ID: 11747327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
    Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
    Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.
    Bezjak A; Tu D; Seymour L; Clark G; Trajkovic A; Zukin M; Ayoub J; Lago S; de Albuquerque Ribeiro R; Gerogianni A; Cyjon A; Noble J; Laberge F; Chan RT; Fenton D; von Pawel J; Reck M; Shepherd FA;
    J Clin Oncol; 2006 Aug; 24(24):3831-7. PubMed ID: 16921034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen.
    Primrose JN; Bleiberg H; Daniel F; Van Belle S; Mansi JL; Seymour M; Johnson PW; Neoptolemos JP; Baillet M; Barker K; Berrington A; Brown PD; Millar AW; Lynch KP
    Br J Cancer; 1999 Feb; 79(3-4):509-14. PubMed ID: 10027321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer.
    Bramhall SR; Schulz J; Nemunaitis J; Brown PD; Baillet M; Buckels JA
    Br J Cancer; 2002 Jul; 87(2):161-7. PubMed ID: 12107836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma matrix metalloproteinases 7 and 9 in patients with metastatic breast cancer treated with marimastat or placebo: Eastern Cooperative Oncology Group trial E2196.
    Zucker S; Wang M; Sparano JA; Gradishar WJ; Ingle JN; Davidson NE;
    Clin Breast Cancer; 2006 Feb; 6(6):525-9. PubMed ID: 16595036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation.
    Levin VA; Phuphanich S; Yung WK; Forsyth PA; Maestro RD; Perry JR; Fuller GN; Baillet M
    J Neurooncol; 2006 Jul; 78(3):295-302. PubMed ID: 16636750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial.
    Bramhall SR; Rosemurgy A; Brown PD; Bowry C; Buckels JA;
    J Clin Oncol; 2001 Aug; 19(15):3447-55. PubMed ID: 11481349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923.
    Ardizzoni A; Tjan-Heijnen VC; Postmus PE; Buchholz E; Biesma B; Karnicka-Mlodkowska H; Dziadziuszko R; Burghouts J; Van Meerbeeck JP; Gans S; Legrand C; Debruyne C; Giaccone G; Manegold C;
    J Clin Oncol; 2002 Oct; 20(19):3947-55. PubMed ID: 12351591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Marimastat (BB2516): current status of development.
    Steward WP
    Cancer Chemother Pharmacol; 1999; 43 Suppl():S56-60. PubMed ID: 10357560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer.
    Miller KD; Gradishar W; Schuchter L; Sparano JA; Cobleigh M; Robert N; Rasmussen H; Sledge GW
    Ann Oncol; 2002 Aug; 13(8):1220-4. PubMed ID: 12181245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.